BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Xtent Inc. Announces Pricing Of Initial Public Offering


2/2/2007 9:37:15 AM

MENLO PARK, Calif., Feb. 1 /PRNewswire-FirstCall/ -- XTENT, Inc. (Nasdaq: XTNT - News) today announced the initial public offering of 4,700,000 shares of common stock at a price of $16.00 per share. XTENT has granted the underwriters an option to purchase up to an additional 705,000 shares at the initial public offering price to cover over-allotments, if any. The common stock will trade on the NASDAQ Global Market under the symbol "XTNT".

Piper Jaffray & Co. is the bookrunning manager for the offering. Cowen and Company, LLC, Lazard Capital Markets LLC and RBC Capital Markets Corporation are co-managers.

A registration statement relating to these securities has been filed with, and declared effective by, the Securities and Exchange Commission. This announcement shall not constitute an offer to sell or the solicitation of an offer to buy the common stock of XTENT, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Copies of the final prospectus may be obtained from the offices of Piper Jaffray & Co. at 800 Nicollet Mall, Suite 800, Minneapolis, Minnesota 55402; Cowen and Company, LLC at ADP, 1155 Long Island Avenue, Edgewood, NY 11717; Lazard Capital Markets LLC at 30 Rockefeller Plaza, New York, NY 10020; and RBC Capital Markets Corporation at One Liberty Plaza, 165 Broadway, New York, NY 10006.

About XTENT, Inc.

XTENT, Inc. is a medical device company focused on developing and commercializing innovative customizable drug eluting stent (DES) systems for the treatment of coronary artery disease (CAD). CAD is the most common form of cardiovascular disease and the number one cause of death in the United States and Europe. XTENT® Custom NX(TM) DES Systems are designed to enable the treatment of single lesions, long lesions and multiple lesions of varying lengths and diameters, in one or more arteries with a single device.

Source: XTENT, Inc.

>>> Discuss This Story



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES